febuxostat has been researched along with Chronic Kidney Diseases in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 53 (67.95) | 24.3611 |
| 2020's | 25 (32.05) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, P; Li, X; Liu, J; Ma, L | 1 |
| Azushima, K; Kanaoka, T; Kinguchi, S; Okami, N; Tamura, K; Tsukamoto, S; Uneda, K; Wakui, H; Yamada, T; Yamaji, T | 1 |
| Kashiwagi, T; Sakai, Y; Yamada, T | 1 |
| Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR | 1 |
| Hosoya, T; Iwasa, N; Kataoka, H; Kimura, K; Mochizuki, T; Nitta, K; Ohara, M; Tsuchiya, K; Tsuruta, Y; Yoshida, R | 1 |
| Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y | 1 |
| Burianov, OA; Danyliuk, SV; Khimion, LV; Nayshtetik, IM; Rotova, SO; Smiyan, SI; Trofanchuk, VV | 1 |
| Cai, Y; Cai, Z; Chen, T; Huang, X; Mi, X; Shui, G; Wang, F | 1 |
| Cao, B; Yang, N | 1 |
| Chen, X; Feng Li, H; Hong, Y; Li, Z; Wang, G; Wang, Y; Wu, W; Zhang, X; Zhou, C; Zhou, D | 1 |
| Abdellatif, YA; Saad, RE; Sarhan, II; Teama, NM | 1 |
| Mironova, OI | 1 |
| Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R | 1 |
| Inkong, P; Nata, N; Ninwisut, N; Satirapoj, B; Supasyndh, O | 1 |
| Chen, JS; Chiou, MJ; Chung, TT; Hsieh, AH; Kuo, CF; Lan, WC; Luo, SF; Tseng, WY; Wang, LC; Yu, KH | 1 |
| Anderson, GF; Chang, SH; Chen, YC; Hsiao, CY; Hsu, YO; Huang, YT; Hung, CC; Kuo, CF; Kuo, G; Lee, CC; Lin, CY; Lin, HL; Lin, WT; Tian, YC; Tsai, CY; Wu, CY; Wu, IW; Yang, CC; Yang, CW; Yang, HY; Yen, TH | 1 |
| Peng, Q; Wan, D; Wang, X; Yang, G; Zhang, X | 1 |
| Yang, AY | 1 |
| Baek, CH; Chang, JW; Kim, H; Lee, SK; Yang, WS | 1 |
| Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG | 1 |
| Brown, JN; Hu, AM | 1 |
| Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G | 1 |
| Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH | 1 |
| Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB | 1 |
| Chertow, GM; Jalal, DI | 1 |
| Badve, SV; Johnson, DW; Tiku, A | 2 |
| Neogi, T; Vargas-Santos, AB | 1 |
| Harada, M; Hashimoto, K; Kamijo, Y; Yamada, Y; Yamaguchi, A | 1 |
| Borghi, C; Bove, M; Cicero, AFG | 1 |
| Bolignano, D; Buemi, M; Cernaro, V; D'Arrigo, G; Gembillo, G; Pisano, A | 1 |
| Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC | 1 |
| Case, R; Jester, G; Wentworth, B | 1 |
| Balia, F; Borrelli, S; De Nicola, L; De Stefano, T; Garofalo, C; Minutolo, R; Nettuno, F; Pacilio, M; Sagliocchi, A; Scarpati, L; Sguazzo, A; Vinci, G; Vita, C | 1 |
| Treviño-Becerra, A | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Madero, M; Ramirez-Sandoval, JC | 1 |
| Hu, K; Liu, J; Tang, Y; Wang, J; Xu, J; Zeng, XX; Zhou, X; Zhu, L | 1 |
| Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H | 1 |
| Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M | 1 |
| Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X | 1 |
| Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A | 1 |
| Cheetham, TC; Levy, G; Rashid, N; Shi, JM | 1 |
| Chae, DW; Cho, HS; Cho, YJ; Hwang, JH; Jee, YK; Jeong, YY; Jun, JB; Jung, HY; Jung, JW; Kang, MG; Kim, DK; Kim, GH; Kim, HY; Kim, JY; Kim, MH; Kim, S; Kim, SH; Kim, SJ; Kim, SM; Kwon, SK; Lee, EK; Lee, JM; Lee, JP; Oh, YK; Park, HW; Park, JS; Ryu, DR; Shin, J; Yang, MS | 1 |
| Lee, JW; Lee, KH | 1 |
| Kim, JM; Kim, SH; Lee, SY; Son, CN | 1 |
| Ahn, C; Bae, EH; Choi, HS; Kim, CS; Kim, SW; Kim, YS; Ma, SK; Oh, KH; Oh, TR; Sung, SA | 1 |
| Chen, YC; Hung, LY; Lin, CH; Lin, TC; Lo, WC; Tam, KW; Wu, MY | 1 |
| Hosoya, T; Kobayashi, S; Ogura, M | 1 |
| Ohno, I | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Dhakad, U; Dhaon, P; Wakhlu, A | 1 |
| Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T | 1 |
| Bae, EJ; Chang, SH; Cho, HS; Jang, HN; Kang, Y; Kim, MJ; Park, DJ; Yun, S | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Ohya, M; Shigematsu, T | 1 |
| Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y | 1 |
| Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y | 1 |
| Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H | 1 |
| Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T | 1 |
| Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K | 1 |
| Chatterjee, S; Golay, V; Pandey, R; Raychaudhury, A; Sircar, D; Waikhom, R | 1 |
| Cheetham, TC; Levy, G | 1 |
| Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET | 1 |
| Bakinde, N; Mome, R | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Echizen, H; Hirai, T; Kimura, T | 1 |
| Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ | 1 |
| Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P | 1 |
| Ahn, SM; Choi, SW; Hong, S; Kim, YG; Lee, CK; Lim, DH; Oh, JS; Yoo, B | 1 |
| Bailly, F; Bardin, T; Chalès, G; Cornec, D; Cornec-Le Gall, E; Dieudé, P; Ea, HK; Flipo, RM; Juge, PA; Lioté, F; Loustau, C; Ottaviani, S; Pascart, T; Pillebout, E; Richette, P; Saraux, A; Schaeverbeke, T; Snanoudj, R; Truchetet, ME; Vigneau, C | 1 |
| Gavriilaki, E; Kalaitzoglou, A; Papaioannou, G; Paschou, E; Sabanis, N; Tsompanakou, A | 1 |
| Stamp, LK | 1 |
| Hoshi, H; Kazama, JJ; Terawaki, H | 1 |
| Curiel, RV; Guzman, NJ | 1 |
| Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J | 1 |
18 review(s) available for febuxostat and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Network Meta-Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Topics: Disease Progression; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Uric Acid | 2021 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Xanthine Oxidase | 2017 |
[Hyperuricaemia and Chronic Kidney Disease].
Topics: Allopurinol; Arteriosclerosis; Disease Progression; Febuxostat; Humans; Hypertension; Hyperuricemia; Observational Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors | 2018 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney; Parenchymal Tissue; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Treatment of Hyperuricemia in Chronic Kidney Disease.
Topics: Allopurinol; Diet; Disease Progression; Exercise; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Life Style; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Weight Loss | 2018 |
Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic | 2018 |
Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.
Topics: Disease Progression; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
[The cutting-edge of medicine; role of hyperuricemia in cardiorenal syndrome].
Topics: Cardio-Renal Syndrome; Febuxostat; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome | 2013 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2017 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Contraindications; Febuxostat; Glucocorticoids; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Probenecid; PubMed; Renal Insufficiency, Chronic; Secondary Prevention; Thiazoles; Urate Oxidase | 2012 |
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2013 |
14 trial(s) available for febuxostat and Chronic Kidney Diseases
| Article | Year |
|---|---|
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Febuxostat; Fibronectins; Hyperuricemia; Inflammasomes; Interleukin-18; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Renal Insufficiency, Chronic; Uric Acid; Vimentin | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Renoprotective effect of febuxostat on contrast-induced acute kidney injury in chronic kidney disease patients stage 3: randomized controlled trial.
Topics: Acute Kidney Injury; Contrast Media; Coronary Angiography; Febuxostat; Humans; Percutaneous Coronary Intervention; Renal Insufficiency, Chronic; Risk Factors | 2023 |
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2023 |
Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Topics: C-Reactive Protein; Febuxostat; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid; Vascular Diseases | 2023 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2020 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Hyperuricemia; Kidney Calculi; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2018 |
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delayed-Action Preparations; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; gamma-Glutamyltransferase; Glomerular Filtration Rate; Gout; Gout Suppressants; Headache; Humans; Hypertension; Male; Middle Aged; Naproxen; Nasopharyngitis; Renal Insufficiency, Chronic; Respiratory Tract Infections; Severity of Illness Index; Treatment Outcome; Uric Acid | 2019 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Japan; Kidney; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Risk Factors; Severity of Illness Index; Tablets; Thiazoles; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2014 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Renal Insufficiency, Chronic; Triglycerides; Uric Acid | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Proteins; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2015 |
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Adult; Aged; Asymptomatic Diseases; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; India; Male; Middle Aged; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2015 |
46 other study(ies) available for febuxostat and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
Topics: Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
Topics: Allopurinol; China; Cost-Benefit Analysis; East Asian People; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic | 2023 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Recovery of Function; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Uricosuric Agents | 2019 |
Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Databases, Factual; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Taiwan; Young Adult | 2020 |
Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Topics: Aged; Allopurinol; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression.
Topics: AMP-Activated Protein Kinases; Animals; Benzamides; Cell Line; Drug Evaluation, Preclinical; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Febuxostat; Heme Oxygenase-1; Humans; Mice; Naphthols; Renal Insufficiency, Chronic; Signal Transduction; Sirtuin 1; Thioredoxins; Tunicamycin; Xanthine Oxidase | 2020 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Emergency Service, Hospital; Ethnicity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Singapore; Treatment Outcome; Uric Acid | 2020 |
A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2020 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Taiwan; Uric Acid | 2020 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Febuxostat; Humans; Naphthalenes; Propionates; Pyridines; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Symptom Flare Up; Treatment Outcome; Uric Acid | 2017 |
Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Comorbidity; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Longitudinal Studies; Male; Middle Aged; Prevalence; Renal Agents; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Sex Distribution; Treatment Outcome; Uric Acid; Vascular Diseases; Young Adult | 2017 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Taiwan; Uric Acid; Uricosuric Agents | 2018 |
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gout Suppressants; Humans; Male; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Treatment Outcome; Uric Acid | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Odds Ratio; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Uric Acid; Young Adult | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Severity of Illness Index; Uric Acid; Uricosuric Agents | 2018 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Efficacy of the HLA-B
Topics: Aged; Allergens; Allopurinol; Drug Hypersensitivity; Febuxostat; Female; Genotype; Histocompatibility Testing; HLA-B Antigens; Humans; Korea; Male; Mass Screening; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Risk; Skin | 2019 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Uric Acid | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Treatment Outcome; Uric Acid | 2020 |
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Topics: Adult; Aged; Biomarkers; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Patient Outcome Assessment; Propensity Score; Public Health Surveillance; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2019 |
Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Neutropenia; Renal Insufficiency, Chronic; Thiazoles | 2013 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid | 2014 |
Irregular gout.
Topics: Chelating Agents; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Lead Poisoning; Male; Occupational Diseases; Occupational Exposure; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease.
Topics: Aged; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic; Rhabdomyolysis; Thiazoles | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Endpoint Determination; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Is It Time to Start Treating Asymptomatic Hyperuricemia?
Topics: Asymptomatic Diseases; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic | 2015 |
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Uric Acid | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal Insufficiency, Chronic; Uric Acid; Xanthine; Xanthine Oxidase | 2016 |
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Pharmaceutical Services; Renal Insufficiency, Chronic; United States; Uric Acid; Young Adult | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
Febuxostat in Hyperuricemic Patients With Advanced CKD.
Topics: Adult; Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index | 2016 |
Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.
Topics: Academic Medical Centers; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Febuxostat; Female; Follow-Up Studies; France; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Patient Safety; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2017 |
Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?
Topics: Drug Hypersensitivity Syndrome; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Renal Insufficiency, Chronic | 2016 |
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Topics: Aged; Aged, 80 and over; Drug Substitution; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Proteinuria; Pyridines; Renal Insufficiency, Chronic; Treatment Outcome; Xanthine Dehydrogenase; Xanthine Oxidase | 2017 |